Eli Lilly Earnings Estimate

LLY Stock  USD 813.48  0.00  0.00%   
The next projected EPS of Eli Lilly is estimated to be 4.6911 with future projections ranging from a low of 4.2 to a high of 5.36. Eli Lilly's most recent 12-month trailing earnings per share (EPS TTM) is at 11.71. Please be aware that the consensus of earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Eli Lilly is projected to generate 4.6911 in earnings per share on the 31st of March 2025. Eli Lilly earnings estimates show analyst consensus about projected Eli Lilly and EPS (Earning Per Share). It derives the highest and the lowest estimates based on Eli Lilly's historical volatility. Many public companies, such as Eli Lilly, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Eli Lilly Revenue Breakdown by Earning Segment

By analyzing Eli Lilly's earnings estimates, investors can diagnose different trends across Eli Lilly's analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about 38.5 B in 2025, whereas Pretax Profit Margin is likely to drop 0.25 in 2025.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Eli Lilly Earnings Estimation Breakdown

The calculation of Eli Lilly's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eli Lilly is estimated to be 4.6911 with the future projection ranging from a low of 4.2 to a high of 5.36. Please be aware that this consensus of annual earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
5.32
4.20
Lowest
Expected EPS
4.6911
5.36
Highest

Eli Lilly Earnings Projection Consensus

Suppose the current estimates of Eli Lilly's value are higher than the current market price of the Eli Lilly stock. In this case, investors may conclude that Eli Lilly is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eli Lilly's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
2882.32%
5.32
4.6911
11.71

Eli Lilly Earnings History

Earnings estimate consensus by Eli Lilly analysts from Wall Street is used by the market to judge Eli Lilly's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Eli Lilly's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Eli Lilly Quarterly Gross Profit

11.13 Billion

Price Earnings Ratio is likely to rise to 68.70 in 2025, whereas Retained Earnings are likely to drop slightly above 9.6 B in 2025. Common Stock Shares Outstanding is likely to drop to about 864.7 M in 2025. Net Income Applicable To Common Shares is likely to drop to about 4 B in 2025.
Hype
Prediction
LowEstimatedHigh
809.04811.07894.83
Details
Intrinsic
Valuation
LowRealHigh
782.85784.88894.83
Details
Naive
Forecast
LowNextHigh
766.40768.43770.46
Details
28 Analysts
Consensus
LowTargetHigh
895.48984.051,092
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Eli assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Eli Lilly. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Eli Lilly's stock price in the short term.

Eli Lilly Earnings per Share Projection vs Actual

Actual Earning per Share of Eli Lilly refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eli Lilly and predict the company's earnings will be in the future. The higher the earnings per share of Eli Lilly, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Eli Lilly Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Eli Lilly, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eli Lilly should always be considered in relation to other companies to make a more educated investment decision.

Eli Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Eli Lilly's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-06
2024-12-315.06685.320.2532
2024-10-30
2024-09-301.471.18-0.2919 
2024-08-08
2024-06-302.63.921.3250 
2024-04-30
2024-03-312.462.580.12
2024-02-06
2023-12-312.222.490.2712 
2023-11-02
2023-09-30-0.130.10.23176 
2023-08-08
2023-06-301.982.110.13
2023-04-27
2023-03-311.731.62-0.11
2023-02-02
2022-12-311.782.090.3117 
2022-11-01
2022-09-301.921.980.06
2022-08-04
2022-06-301.691.25-0.4426 
2022-04-28
2022-03-312.322.770.4519 
2022-02-03
2021-12-312.462.490.03
2021-10-26
2021-09-301.981.94-0.04
2021-08-03
2021-06-301.891.87-0.02
2021-04-27
2021-03-312.131.87-0.2612 
2021-01-29
2020-12-312.352.750.417 
2020-10-27
2020-09-301.711.54-0.17
2020-07-30
2020-06-301.561.890.3321 
2020-04-23
2020-03-311.481.750.2718 
2020-01-30
2019-12-311.521.730.2113 
2019-10-23
2019-09-301.411.480.07
2019-07-30
2019-06-301.451.50.05
2019-04-30
2019-03-311.311.330.02
2019-02-06
2018-12-311.341.33-0.01
2018-11-06
2018-09-301.351.390.04
2018-07-24
2018-06-301.31.50.215 
2018-04-24
2018-03-311.131.340.2118 
2018-01-31
2017-12-311.071.140.07
2017-10-24
2017-09-301.031.050.02
2017-07-25
2017-06-301.051.110.06
2017-04-25
2017-03-310.960.980.02
2017-01-31
2016-12-310.980.95-0.03
2016-10-25
2016-09-300.960.88-0.08
2016-07-26
2016-06-300.860.860.0
2016-04-26
2016-03-310.850.83-0.02
2016-01-28
2015-12-310.780.780.0
2015-10-22
2015-09-300.760.890.1317 
2015-07-23
2015-06-300.740.90.1621 
2015-04-23
2015-03-310.770.870.112 
2015-01-30
2014-12-310.730.750.02
2014-10-23
2014-09-300.670.66-0.01
2014-07-24
2014-06-300.650.680.03
2014-04-24
2014-03-310.70.70.0
2014-01-30
2013-12-310.740.740.0
2013-10-23
2013-09-301.041.110.07
2013-07-24
2013-06-3011.160.1616 
2013-04-24
2013-03-311.051.140.09
2013-01-29
2012-12-310.780.850.07
2012-10-24
2012-09-300.830.79-0.04
2012-07-25
2012-06-300.770.830.06
2012-04-25
2012-03-310.780.920.1417 
2012-01-31
2011-12-310.810.870.06
2011-10-20
2011-09-301.131.130.0
2011-07-21
2011-06-301.181.180.0
2011-04-18
2011-03-311.171.240.07
2011-01-27
2010-12-311.11.110.01
2010-10-21
2010-09-301.151.210.06
2010-07-22
2010-06-301.11.240.1412 
2010-04-19
2010-03-311.11.180.08
2010-01-28
2009-12-310.920.91-0.01
2009-10-21
2009-09-301.021.20.1817 
2009-07-22
2009-06-301.021.120.1
2009-04-20
2009-03-310.991.20.2121 
2009-01-29
2008-12-311.051.070.02
2008-10-23
2008-09-301.021.040.02
2008-07-24
2008-06-3010.99-0.01
2008-04-21
2008-03-310.960.92-0.04
2008-01-29
2007-12-310.890.90.01
2007-10-18
2007-09-300.870.910.04
2007-07-24
2007-06-300.820.90.08
2007-04-16
2007-03-310.790.840.05
2007-01-31
2006-12-310.820.850.03
2006-10-19
2006-09-300.790.80.01
2006-07-21
2006-06-300.750.760.01
2006-04-20
2006-03-310.750.770.02
2006-01-26
2005-12-310.780.80.02
2005-10-20
2005-09-300.710.730.02
2005-07-21
2005-06-300.670.670.0
2005-04-18
2005-03-310.660.680.02
2005-01-26
2004-12-310.740.750.01
2004-10-21
2004-09-300.680.690.01
2004-07-22
2004-06-300.680.680.0
2004-04-19
2004-03-310.660.70.04
2004-01-29
2003-12-310.670.670.0
2003-10-22
2003-09-300.660.660.0
2003-07-24
2003-06-300.60.640.04
2003-04-22
2003-03-310.580.610.03
2003-01-23
2002-12-310.680.680.0
2002-10-23
2002-09-300.680.680.0
2002-07-18
2002-06-300.610.610.0
2002-04-15
2002-03-310.580.580.0
2002-01-24
2001-12-310.60.60.0
2001-10-18
2001-09-300.660.660.0
2001-07-19
2001-06-300.740.760.02
2001-04-16
2001-03-310.730.740.01
2001-01-25
2000-12-310.70.70.0
2000-10-19
2000-09-300.710.710.0
2000-07-20
2000-06-300.60.610.01
2000-04-17
2000-03-310.610.630.02
2000-01-27
1999-12-310.610.610.0
1999-10-20
1999-09-300.620.620.0
1999-07-21
1999-06-300.510.520.01
1999-04-19
1999-03-310.530.530.0
1999-01-28
1998-12-310.510.5-0.01
1998-10-21
1998-09-300.510.530.02
1998-07-22
1998-06-300.430.450.02
1998-04-20
1998-03-310.460.470.01
1998-01-29
1997-12-310.420.41-0.01
1997-10-20
1997-09-300.40.410.01
1997-07-23
1997-06-300.380.380.0
1997-04-21
1997-03-310.40.410.01
1997-01-27
1996-12-310.340.340.0
1996-10-22
1996-09-300.320.380.0618 
1996-07-16
1996-06-300.320.320.0
1996-04-15
1996-03-310.360.360.0

About Eli Lilly Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Eli Lilly earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Eli Lilly estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Eli Lilly fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings13.5 B9.6 B
Retained Earnings Total Equity11.5 B10.8 B
Earnings Yield 0.02  0.01 
Price Earnings Ratio 65.43  68.70 
Price Earnings To Growth Ratio 0.64  0.34 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Eli Stock Analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.